Chelsea Therapeutics   
Chelsea Therapeutics International Ltd.是生技制药公司，从事类风湿性关节炎、牛皮癣、癌症及其它免疫系统混乱的治疗用药。该公司重点研究中的新药CH-1504，则是一种口服型的消炎、抗癌药物

 
Chelsea Therapeutics (Nasdaq:CHTP) is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases, including central nervous system disorders. Chelsea is currently pursuing FDA approval in the U.S. for Northera™ (droxidopa), a novel, late-stage, orally-active therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension in patients with primary autonomic failure.